Quadrant Capital Group’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,157
| Closed | -$25.2K | – | 2404 |
|
|
2026
Q1 | $25.2K | Sell |
1,157
-31
| -3% | -$600 | ﹤0.01% | 1926 |
|
|
2025
Q4 | $25.6K | Sell |
1,188
-23
| -2% | -$485 | ﹤0.01% | 1911 |
|
|
2025
Q3 | $23.3K | Sell |
1,211
-12,066
| -91% | -$215K | ﹤0.01% | 1903 |
|
|
2025
Q2 | $227K | Buy |
13,277
+12,706
| +2,225% | +$542K | 0.01% | 1252 |
|
|
2025
Q1 | $36.4K | Sell |
571
-271
| -32% | -$28.5K | ﹤0.01% | 1831 |
|
|
2024
Q4 | $102K | Sell |
842
-24
| -3% | -$2.94K | 0.01% | 1037 |
|
|
2024
Q3 | $108K | Buy |
866
+303
| +54% | +$41.9K | 0.01% | 1024 |
|
|
2024
Q2 | $89K | Buy |
563
+482
| +595% | +$61.9K | 0.01% | 1078 |
|
|
2024
Q1 | $10.5K | Buy |
81
+12
| +17% | +$1.47K | ﹤0.01% | 2088 |
|
|
2023
Q4 | $6.65K | Buy |
69
+31
| +82% | +$2.97K | ﹤0.01% | 2199 |
|
|
2023
Q3 | $4.61K | Buy |
38
+1
| +3% | +$113 | ﹤0.01% | 2198 |
|
|
2023
Q2 | $4.24K | Sell |
37
-90
| -71% | -$11.6K | ﹤0.01% | 2244 |
|
|
2023
Q1 | $17.5K | Buy |
127
+95
| +297% | +$12.3K | ﹤0.01% | 1760 |
|
|
2022
Q4 | $4.15K | Sell |
32
-25
| -44% | -$2.9K | ﹤0.01% | 2246 |
|
|
2022
Q3 | $6K | Sell |
57
-89
| -61% | -$8.97K | ﹤0.01% | 2094 |
|
|
2022
Q2 | $11K | Sell |
146
-163
| -53% | -$12K | ﹤0.01% | 1623 |
|
|
2022
Q1 | $24K | Sell |
309
-465
| -60% | -$35.6K | ﹤0.01% | 1251 |
|
|
2021
Q4 | $70K | Sell |
774
-7
| -0.9% | -$598 | 0.01% | 793 |
|
|
2021
Q3 | $72K | Buy |
781
+600
| +331% | +$46.2K | 0.01% | 736 |
|
|
2021
Q2 | $14K | Buy |
181
+142
| +364% | +$10.8K | ﹤0.01% | 1400 |
|
|
2021
Q1 | $3K | Sell |
39
-33
| -46% | -$3.04K | ﹤0.01% | 1988 |
|
|
2020
Q4 | $12K | Buy |
72
+30
| +71% | +$4.45K | ﹤0.01% | 1312 |
|
|
2020
Q3 | $6K | Sell |
42
-3
| -7% | -$456 | ﹤0.01% | 1484 |
|
|
2020
Q2 | $7K | Sell |
45
-186
| -81% | -$25.3K | ﹤0.01% | 1518 |
|
|
2020
Q1 | $22K | Buy |
231
+218
| +1,677% | +$24.9K | ﹤0.01% | 1242 |
|
|
2019
Q4 | $1K | Buy |
+13
| New | +$1.31K | ﹤0.01% | 2353 |
|
|
2019
Q3 | – | Sell |
-389
| Closed | -$58K | – | 2382 |
|
|
2019
Q2 | $58K | Sell |
389
-52
| -12% | -$6.32K | 0.01% | 1149 |
|
|
2019
Q1 | $51K | Buy |
+441
| New | +$56.7K | 0.01% | 1208 |
|
|
2018
Q4 | – | Sell |
-6
| Closed | – | – | 2287 |
|
|
2018
Q3 | $0 | Buy |
+6
| New | +$820 | ﹤0.01% | 2185 |
|
Other funds holding SRPT
EAM
Quadrant Capital Group's SRPT Position: Q2 2026 in Review
Quadrant Capital Group sold out of Sarepta Therapeutics (SRPT) in Q2 2026, closing a stake of 1,157 shares — an estimated $25.2K sold.
Quadrant Capital Group first reported a position in SRPT in Q3 2018 and held it in 29 quarters. The position peaked at $227K in Q2 2025. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.
- Quadrant Capital Group reported no remaining Sarepta Therapeutics position as of Q2 2026 after selling out during the quarter.
- Quadrant Capital Group sold 1,157 Sarepta Therapeutics shares in Q2 2026, an estimated $25.2K.
- Quadrant Capital Group first reported a position in Sarepta Therapeutics in Q3 2018 and held it in 29 quarters.
- Quadrant Capital Group's Sarepta Therapeutics position peaked at $227K in Q2 2025.
- 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.
Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.